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Abstract
In this study we describe the sociodemographic characteristics of people participating in a clinical trial on the
safety and immunogenicity of a H5N1 influenza vaccine and we identify the main motivations for joining it.
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Recently, the appearance of new influenza strains with
the ability of propagating by human- human transmis-
sion put both the scientific community and the general
public on alert [1,2]. For this reason, the WHO under-
lines the urgency of developing vaccines to meet the
new threat [3]. Knowing the characteristics and motiva-
tions of participants in clinical trials may help to
improve the recruitment phase of future trials. Here, we
describe the sociodemographic characteristics and moti-
vations of people participating in a clinical trial of an
influenza vaccine carried out in a university hospital.
The H5N1-008 trial (GlaxoSmithKline) was a multi-
center phase III, double-blind, clinical trial conducted to
compare the safety and reactogenicity of a monovalent
H5N1 influenza vaccine with that of the licensed seaso-
nal influenza vaccine Fluarix™ [4]. All healthy subjects
aged ≥ 18 years were eligible for the trial. A total of
5,071 volunteers were recruited from 7 European coun-
tries between May and June 2006. Information on local
and general symptoms was recorded by each subject
using diary cards for the first seven days following each
vaccination. Serious adverse events were recorded pro-
spectively, ending at the last visit. The recruitment
methods included talks, pamphlets and posters within
and outside the hospital, medical faculties, outpatient
clinics and other health areas. The study required four
visits at the vaccination center of the hospital at days 0,
21, 42 and 180, and a blood extraction at each visit. Par-
ticipants received two vaccinations at days 0 and 21
(pandemic vaccine or Fluarix™).
A cross-sectional study was carried out, in which all
383 recruits from our center were eligible to participate:
on the last visit each participant was provided with a
self-administered questionnaire of 12 items with closed
answers on socio-demographic data, motivations for
participating, how they learned of the trial, and others.
A total of 364 of 383 subjects (95%) answered the
questionnaire. Characteristics of the participants are pre-
sented in Table 1. When our study population was com-
pared to those who participated in seven European
countries, no differences were found regarding age and
education [4]. The most-common way of learning about
the trial was word of mouth (70.1%; n = 255). Fifty-six
(15.4%) subjects had participated in previous studies of
vaccines or other drug trials. Eighty-seven percent (n =
318) of participants were willing to enroll in similar stu-
dies in the future, and 75.0% of the participants (n =
273) would wish to receive the vaccine if it were to be
licensed by the European Medicines Agency and they
had been in the control group.
The most-frequently reported main motivation for
joining the study was collaboration with science (n =
155; 42.6%), and it was related to several characteristics
of participants (Table 2). It varied non-significantly
according to gender (P =0 . 1 1 ) ,a n di tw a ss t r o n g l y
related to their age (P < 0.001); participants older than
60 years were more likely to report collaboration with
science than the younger age categories, while partici-
pants who reported economic reasons were mostly
younger than 25 years of age. It also varied with the
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any medium, provided the original work is properly cited.education level, the profession of participants, and the
way in which people learned of the study (P = 0.06, 0.01
and < 0.001; respectively). Furthermore, age and the way
of learning about the study were strongly related (P <
0.001).
Motivations for participating in clinical trials can be
briefly summarized as follows: possibility of health bene-
fits, obtaining information on the studied disease, will-
ingness to contribute to scientific projects, trusting of
specific physicians and economic interests [5-7]. Only
19 men and 38 women in our study reported participat-
ing to obtain protection against a possible influenza
pandemic. These results are in accordance with a study
of an HIV vaccine with healthy people, where only 12%
of men and 22% of women agreed strongly that they
were motivated by the possible protection against HIV
[6]. Although it should be taken cautiously, our results
highlight altruistic motives, with 40% of men and 45%
of women reporting wanting to collaborate with science,
in accordance with the literature [7-10]. Results show
that one motivation for participation little explored in
previous studies, the influence of other people, was an
important factor. Most of the participants in our trial
knew somebody related to the study, such as other par-
ticipants who already had enrolled, and 37.6% reported
this motivation for participating. Decisions regarding
participation are strongly related to the social network
of the subject: the attitudes, knowledge and habits of
friends, relatives or colleagues regarding clinical trials
influence the decision to join a trial. The small number
of participants reporting economic reasons in our study
was possibly related to the fact that the amount offered
was low (100€), since it was meant to cover travel
expenses. It predominantly appealed to younger people
for whom the financial incentive was meaningful. Con-
trary, a review carried out among healthy volunteers
Table 1 Basic characteristics of the study population
Number Percentage
Gender
Woman 204 (56.0)
Man 160 (44.0)
Age †
18 to 24 80 (22.0)
25 to 44 161 (44.4)
45 to 60 92 (25.3)
>6 1 30 (8.3)
Education level
Non-university 95 (26.0)
University 269 (73.9)
Profession †
Health 138 (38.7)
Non-health 123 (34.5)
Inactive 96 (26.9)
Knowledge of the study †
Word of mouth 255 (70.1)
Talks 35 (9.6)
Posters/pamphlets 33 (9.1)
Communication media 14 (3.8)
Others 18 (4.9)
Main motivation for participating in the trial
Collaboration with science 155 (42.6)
Influence of other people 137 (37.6)
Protection against pandemic 57 (15.7)
Coverage of expenses 15 (4.1)
Willingness to participate in a similar study in the future
No 15 (4.1)
Yes 318 (87.4)
DK/DA ‡ 31 (8.5)
† Numbers may not add up to the total because of missing values
‡ Did not know/Did not answer
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Main reason to participate
Coverage of
expenses
Collaboration with
science
Protection against
pandemic
Influence of other people related
with the study
P-values †
(n = 15) (n = 155) (n = 57) (n = 137)
n (%)* n (%)* n (%)* n (%)*
Gender 0.11
Woman 8 (3.9) 91 (44.6) 38 (18.6) 67 (32.8) a) 1.0
b) 1.0
c) 0.79
Man 7 (4.4) 64 (40.0) 19 (11.9) 70 (43.8) d) 1.0
e) 0.51
f) 0.16
Age ‡
18 to 24 12 (15.0) 29 (36.3) 10 (12.5) 29 (36.3) < 0.001
25 to 44 3 (1.9) 74 (46.0) 33 (20.5) 51 (31.7) a) 0.03
b) 0.13
c) 0.01
45 to 60 0 (0.0) 37 (40.2) 10 (10.9) 45 (48.9) d) 0.24
e) 0.37
f) 0.10
>6 1 0 (0.0) 15 (50.0) 4 (13.3) 11 (36.7)
Education level 0.06
Non-university 3 (3.2) 34 (35.8) 23 (24.2) 35 (36.8) a) 1.0
b) 0.91
c) 1.0
University 12 (4.5) 121 (45.0) 34 (12.6) 102 (37.9) d) 0.05
e) 1.0
f) 0.29
Profession ‡
Health 1 (0.8) 60 (48.8) 19 (15.4) 43 (35.0) 0.01
Non-health 4 (2.9) 50 (36.2) 26 (18.8) 58 (42.0) a) 0.07
b) 0.27
c) 0.28
Inactive 10 (10.4) 41 (42.7) 12 (12.5) 33 (34.4) d) 0.85
e) 0.65
f) 0.87
Knowledge of the study ‡
Word of mouth 8 (3.1) 95 (37.3) 36 (14.1) 116 (45.5) < 0.001
Talks 1 (2.9) 21 (60.0) 6 (17.1) 7 (20.0) a) 1.0
b) 1.0
c) 0.04
Posters/pamphlets 5 (15.2) 18 (54.5) 6 (18.2) 4 (12.1) d) 1.0
e) < 0.01
f) < 0.01
Communication media 0 (0.0) 6 (42.9) 6 (42.9) 2 (14.3)
Others 0 (0.0) 11 (61.1) 3 (16.7) 4 (22.2)
† Fisher’s exact test for homogeneity of proportions between categories. P-values labelled from a) to b) correspond to the following multiple comparisons, using
Holm correction method: a) Coverage of expenses vs Collaboration with science; b) Coverage of expenses vs Protection against pandemic; c) Coverage of
expenses vs Influence of other people; d) Collaboration with science vs Protection against pandemic; e) Collaboration with science vs Influence of other people; f)
Protection against pandemic vs Influence of other people. Age, profession and knowledge of the study have been recoded as follows for multiple comparisons: <
45 vs 45+, health vs rest of categories, and word of mouth vs rest of categories, respectively
‡ Numbers may not add up to the total because of missing values
* Row percentages
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participation reported in 8 of 12 studies [10]. The fact
that most of the subjects who chose the economic moti-
vation were younger than 25 years shows an interesting
link between the age of participants and their motiva-
tions. An open answer for other possible motivations
was included in the questionnaire. However, only two
people chose this option and in both cases the answer
fell within the scope of the four proposed categories.
The association between the way of learning about the
study and the age of participants suggests that the
recruitment method could appeal to people with differ-
ent characteristics. This fact highlights the importance
of taking the above into account while designing trials
to avoid biased results.
In conclusion, the main reported motivation for parti-
cipating was collaboration with science, and it was
related to several characteristics of the participants. The
strategies involved seemed to appeal to people with dif-
ferent demographics, underscoring the importance of
the recruitment design in order to ensure generalizabil-
ity of results.
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